Highlights Oramed Pharmaceuticals Inc. Deutsche Boerse AG

Equities

OJU1

US68403P2039

Real-time Estimate Tradegate Other stock markets 03:30:24 2024-05-13 am EDT			5-day change	1st Jan Change
2.225 ^EUR	+1.78%		+1.81%	+4.93%

May. 09	Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 19	Oramed Pharmaceuticals Inc. Appoints Yehuda Reznick as Director, Effective as of April 1, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Scilex Consummates Purchase of Securities Owned by Sorrento Therapeutics	23-09-21	MT
Oramed Pharmaceuticals Inc. cancelled the acquisition of 40.17% stake in Scilex Holding Company from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q).	23-09-20	CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Oramed Pharmaceuticals Inc. entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.	23-08-06	CI
Oramed Pharmaceuticals, Hefei Tianhui Biotech Sign Non-Binding Agreement to Form Joint Venture	23-08-02	MT
Oramed Pharmaceuticals Inc. Signs Term Sheet with Hefei Tianhui Biotech Co., Ltd. to Create Joint Venture to Advance Oral Drug Delivery Technology Globally	23-08-02	CI
Oramed Pharmaceuticals Inc. Announces its Chinese Partner, Hefei Tianhui Biotechnology Co. Ltd. Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China	23-05-15	CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-06	CI
Oramed Pharmaceuticals Inc. Announces Top-Line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes	23-01-11	CI
Oramed Pharmaceuticals Secures US Patent for Diabetes Combination Therapy	23-01-04	MT
Oramed Pharmaceuticals Inc. Granted U.S. Combination Therapy Patent for Oral Glp-1 & Insulin for the Treatment of Diabetes	23-01-04	CI
Oramed Pharmaceuticals Reports Additional Positive Mid-Stage Data for Oral Insulin Candidate	22-11-17	MT
Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH	22-11-17	CI
Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea	22-11-14	CI
Earnings Flash (ORMP) ORAMED PHARMACEUTICALS Reports Q3 Revenue $682,000	22-11-10	MT
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Oramed Pharmaceuticals Inc. Deutsche Boerse AG

Equities

OJU1

US68403P2039

Highlights

Filters